- July 28, 2010
- By Samer Habbas, Esq
- In Drug Recalls,
On July 16, 2010, the Food and Drug Administration (FDA) decided to keep the diabetes drug Avandia (rosiglitazone) on the market despite a cardiovascular threat to some patients. Conflicting studies have shown that the drug rosiglitazone promotes increased cardiovascular risk to patients with diabetes. The FDA, as well as the Endocrine Society, the American Association […]